Protein diagnostic biomarker for severe drug eruption

A method of diagnosing severe cutaneous adverse drug reactions, comprising:

• a3. obtaining a sample from a subject;
• b3. measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in the sample from the subject;
• and
• c3. assessing the severity of drug eruption based on the measured values from b3.

A method of diagnosing severe cutaneous adverse drug reactions, comprising:

• a2. obtaining a sample from a subject;
• b2. measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in the sample from the subject;
• and
• c2. determining the disease activity of severe cutaneous adverse drug reactions based on the measured values from b2.

A method of diagnosing severe cutaneous adverse drug reactions, comprising:

• a4. obtaining a sample from a subject;
• b4. measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in the sample from the subject;
• and
• c4. judging the disease type of severe cutaneous adverse drug reactions based on the measured values from b4.

A method of diagnosing and treating severe cutaneous adverse drug reactions, comprising:

• a3. obtaining a sample from a subject;
• b3. measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in the sample from the subject;
• c3. assessing the severity of drug eruption based on the measured values from b3;
• and
• d3. stopping the administration of the suspect drug which has been administered to the subject, and starting an appropriate treatment according to the severity of the drug eruption, if it is judged that the subject is highly likely to develop or to have developed severe cataneous adverse drug reactions.

A method of diagnosing and treating severe cutaneous adverse drug reactions, comprising:

• a2. obtaining a sample from a subject;
• b2. measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in the sample from the subject;
• c2. determining the disease activity of severe cutaneous adverse drug reactions based on the measured values from b2;
• and
• d2. stopping the administration of the suspect drug which has been administered to the subject, and starting an appropriate treatment, if it is determined that the subject is highly likely to be in an acute phase.

A method of diagnosing and treating severe cutaneous adverse drug reactions, comprising:

• a4. obtaining a sample from a subject;
• b4. measuring the expression of at least one protein selected from the group consisting of stratifin, TNF receptor superfamily member 8 (CD30/TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3/TNFRSF6B) in the sample from the subject;
• c4. judging the disease type of severe cutaneous adverse drug reactions based on the measured values from b4;
• and
• d4. stopping the administration of the suspect drug which has been administered to the subject, and starting an appropriate treatment according to the disease type of severe cutaneous adverse drug reactions.